Microsoft word - articulo indexado nefritis lupica - agosto 201
Volume 9, Issue 11, September 2010, Pages 750-755
Single anti-P ribosomal antibodies are not associated with lupus nephritis in patients suffering from
active systemic lupus erythematosus
Gerardo Quintanaa, b, , Paola Coral-Alvaradoc, d, Gustavo Arocae, Paul Mendez
Patarroyod, Philippe Chalemd, Antonio Iglesias-Gamarraa, Ariel Ivan Ruiza and Ricard
a School of Medicine, Universidad Nacional de Colombia, Bogota, Colombia
b Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Catalonia, Spain
c Rheumatology Section, Fundación Santa Fe de Bogota, Bogota, Colombia
d Fundación Instituto de Reumatología Fernando Chalem, Bogota, Colombia
e Nephrology Unit, Clínica de la Costa, Universidad Simón Bolívar, Barranquilla, Colombia
In clinical practice, it is sometimes difficult to diagnose a relapse in patients suffering from systemic lupus erythematosus (SLE) and lupus nephritis (LN) having potential complications, including renal failure and death. Some immunological markers can help to determine their association with LN and, therefore, diagnose the early onset of complications.
Evaluating the association between systemic and/or kidney activity and anti-P ribosomal and anti-dsDNA antibodies in patients suffering from active SLE.
389 patients were evaluated, 140 of whom were subsequently included in the study. The patients were divided into two groups by means of case–control studies, including Colombian patients having American College of Rheumatology (ACR) classification criteria for SLE (1997). The SLE disease activity index (SLEDAI) was applied and all patients presenting an increase of 5 or more compared to their last evaluation, as well as presenting renal manifestations, were considered to be cases; all patients had an activity score. An ELISA kit and the indirect immunofluorescence method with Crithidia luciliae
were used for determining the presence of anti-P ribosomal and anti-dsDNA antibodies, respectively.
No association was found between anti-P ribosomal antibodies and LN (p
= 0.2971) but anti-P ribosomal antibodies showed association with a > 5 SLEDAI score (OR = 4.87; 1.32–17.98 95% CI; p
= 0.008). The coexistence of anti-P ribosomal and anti-dsDNA antibodies was associated with LN (OR = 3.52; 1.07–13.42 95% CI; p
= 0.019) and anti-dsDNA was associated with LN (p
There was no association between anti-P ribosomal antibodies and LN but anti-P ribosomal antibodies coexisting with anti-dsDNA antibodies was associated with LN, thereby suggesting that the coexistence of two antibodies is nephritogenic to a greater extent. Additional studies are needed to evaluate the coexistence of kidney-specific antibodies in SLE to determine the biological nature of LN.
SLE, systemic lupus erythematosus; LN, lupus nephritis; ALN, active LN; AZP,
azathioprine; MPN, methylprednisolone; CYC, cyclophosphamide; MFM, mycophenolate
mophetyl; CHQ, chloroquine; MTX, methotrexate; PDN, prednisolone; DFZ, deflazacort; HCQ,
hydroxychloroquine; LFM, leflunomide; RTX, rituximab; dsDNA, double stranded anti-DNA;
NPM, neuropsychiatric manifestation
Fig. 1. Anti-dsDNA antibody in Colombian patients suffering from SLE according to renal involvement. View Within Article
Fig. 2. SLEDAI scores for Colombian patients suffering from SLE. View Within Article
____________________________________________________________ MOHS' MICROSCOPICALLY CONTROLLED SURGERY Thomas E. Rohrer, M.D. Mohs' and Dermatologic Surgery Skin Care Physicians of Chestnut Hill 1244 Boylston Street, Suite 302 Chestnut Hill, MA 02467 Appointments: (617) 848 - 1620 Main number: (617) 731 - 1600 _____________________________
The rules for Development & Enterprise Market (DEM) companies THE STOCK EXCHANGE OF MAURITIUS LTD Contents Introduction Entry requirements Eligibility for the Development & Enterprise Market (DEM) Special conditions for certain applicants On-going requirements Interim (quarterly) financial statements Insiders’ interests and changes in